Physician profile
Mark A Yates
NPI 1992724256
$5,324.60
in general payments reported to CMS, 2019-2025
22 companies · $1,427 in 2025
The $1,427 reported for 2025 was more than what 95% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $282 · 2020: $391 · 2021: $467 · 2022: $416 · 2023: $1,348 · 2024: $995 · 2025: $1,427.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,769.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,768.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $1,158.05 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Allergan, INC. | $562.49 | 2019-2021 | |
| Johnson & Johnson Vision Care, INC. | $468.63 | 2021-2025 | Acuvue |
| Horizon Therapeutics Plc | $416.50 | 2022-2023 | Tepezza |
| Abbvie INC. | $403.34 | 2022-2025 | Durysta, Alphagan P, Lumigan |
| Tarsus Pharmaceuticals, INC. | $368.89 | 2024-2025 | Xdemvy |
| Glaukos Corporation | $242.17 | 2025 | Istent Infinite, Idosetr |
| Alcon Vision LLC | $234.74 | 2024-2025 | Rocklatan |
| Amgen INC. | $219.95 | 2024-2025 | Tepezza |
| Sun Pharmaceutical Industries INC. | $183.32 | 2020-2021 | |
| Harrow Eye, LLC | $156.86 | 2025 | Vevye |
| Kala Pharmaceuticals, INC. | $146.76 | 2020-2021 | |
| Lumenis Be INC | $142.89 | 2023 | M22 |
| Apellis Pharmaceuticals, INC. | $114.04 | 2023 | Syfovre |
| Shire North American Group INC | $110.21 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $109.82 | 2022 | |
| Dompe US, INC. | $109.19 | 2024-2025 | Oxervate |
| Coopervision INC. | $99.26 | 2023 | Myday Contact Lens |
| Aerie Pharmaceuticals, INC. | $24.83 | 2021 | |
| Biotissue Holdings INC. | $20.44 | 2024 | |
| Thea Pharma INC. | $18.22 | 2024 | Iyuzeh |
| Merz North America, INC. | $14.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Yates listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.